Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease

NCT05757141 is registered in ClinicalTrials.gov with Calico Life Sciences LLC as lead sponsor.

NCT NCT05757141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05757141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease
Lead sponsor
Calico Life Sciences LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 13, 2023
Completion date
October 31, 2035
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

vanishing white matter disease